Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eos Energy Enterprises Inc (EOSE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Eos Energy Enterprises IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Eos Energy Enterprises Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.81 (market cap $1.13B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 67.6× Eos Energy Enterprises Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

EOSEREGN
Market Cap
$1.13B$76.40B
Volume
17,918,777626,381
Sector
IndustrialsHealth
52-Week High
$19.19$852.03
52-Week Low
$2.77$557.73
Typical Hold Time
16 Days107 Days
Enterprise Value
$1.47B$71.12B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eos Energy Enterprises Inc

Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.

The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EOSE
17% Buy83% Sell
Avg holding period · 16 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

About Eos Energy Enterprises Inc

Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.

Read more on EOSE →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →